Neisseria gonorrhoeae (Gonorrhea)

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 2, Issue , 2014, Pages 2446-2462.e3

  Marrazzo, Jeanne M ^a   Apicella, Michael A ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Antigenic variation; Antimicrobial resistance; Arthritis; Asialoglycoprotein receptor; Carcinoembryonic antigen related cell adhesion molecules (CEACAMs); Cervicitis; Complement; Complement receptor 3 (CR3); Conjunctivitis; Disseminated gonococcal infection; Epididymitis; Gonorrhea; I domain; Lipo oligosaccharide; Neisseria; Neisseria gonorrhoeae; Opa proteins; Pelvic inflammatory disease; Perihepatitis; Pharyngitis; Phase variation; Pilus; Porin; Sexually transmitted diseases; Urethritis

Indexed keywords

EID: 84944612244     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00214-9     Document Type: Chapter

References (225)

1. Bolan GA, Sparling PF, Wasserheit JN The emerging threat of untreatable gonococcal infection. N Engl J Med 2012, 366:485-487.
2. Kurre R, Hone A, Clausen M, et al. PilT2 enhances the speed of gonococcal type IV pilus retraction and of twitching motility. Mol Microbiol 2012, 86:857-865.
3. Janda W, Gaydos C Neisseria. Manual of Clinical Microbiology 2007, American Society of Microbiology, Washington, DC. 9th ed. P.R. Murray, E.J. Baron, J.H. Jorgensen (Eds.).
4. Chen CJ, Tobiason DM, Thomas CE, et al. A mutant form of the Neisseria gonorrhoeae pilus secretin protein PilQ allows increased entry of heme and antimicrobial compounds. J Bacteriol 2004, 186:730-739.
5. Schoolnik GK, Fernandez R, Tai JY, et al. Gonococcal pili: primary structure and receptor binding domain. J Exp Med 1984, 159:1351-1370.
6. Forest KT, Bernstein SL, Getzoff ED, et al. Assembly and antigenicity of the Neisseria gonorrhoeae pilus mapped with antibodies. Infect Immun 1996, 64:644-652.
7. Kellogg DS, Peacock WL, Deacon WE, et al. Neisseria gonorrhoeae, I. Virulence genetically linked to clonal variation. J Bacteriol 1963, 85:1274-1279.
8. McGee ZA, Johnson AP, Taylor-Robinson D Pathogenic mechanisms of Neisseria gonorrhoeae: observations on damage to human fallopian tubes in organ culture by gonococci of colony type 1 or type 4. J Infect Dis 1981, 143:413-422.
9. Kirchner M, Heuer D, Meyer TF CD46-independent binding of neisserial type IV pili and the major pilus adhesin, PilC, to human epithelial cells. Infect Immun 2005, 73:3072-3082.
10. Rudel T, van Putten JP, Gibbs CP, et al. Interaction of two variable proteins (PilE and PilC) required for pilus-mediated adherence of Neisseria gonorrhoeae to human epithelial cells. Mol Microbiol 1992, 6:3439-3450.
11. Knapp JS, Tam MR, Nowinski RC, et al. Serological classification of Neisseria gonorrhoeae with use of monoclonal antibodies to gonococcal outer membrane protein I. J Infect Dis 1984, 150:44-48.
12. Ram S, Cullinane M, Blom AM, et al. C4bp binding to porin mediates stable serum resistance of Neisseria gonorrhoeae. Int Immunopharmacol 2001, 1:423-432.
13. Ram S, McQuillen DP, Gulati S, et al. Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J Exp Med 1998, 188:671-680.
14. Connell TD, Shaffer D, Cannon JG Characterization of the repertoire of hypervariable regions in the Protein II (opa) gene family of Neisseria gonorrhoeae. Mol Microbiol 1990, 4:439-449.
15. Fischer SH, Rest RF Gonococci possessing only certain P.II outer membrane proteins interact with human neutrophils. Infect Immun 1988, 56:1574-1579.
16. van Putten JP, Duensing TD, Cole RL Entry of OpaA+ gonococci into HEp-2 cells requires concerted action of glycosaminoglycans, fibronectin and integrin receptors. Mol Microbiol 1998, 29:369-379.
17. Wang J, Gray-Owen SD, Knorre A, et al. Opa binding to cellular CD66 receptors mediates the transcellular traversal of Neisseria gonorrhoeae across polarized T84 epithelial cell monolayers. Mol Microbiol 1998, 30:657-671.
18. Boulton IC, Gray-Owen SD Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nat Immunol 2002, 3:229-236.
19. Plummer FA, Chubb H, Simonsen JN, et al. Antibody to Rmp (outer membrane protein 3) increases suscep-tibility to gonococcal infection. J Clin Invest 1993, 91:339-343.
20. Cornelissen CN, Sparling PF Iron piracy: acquisition of transferrin-bound iron by bacterial pathogens. Mol Microbiol 1994, 14:843-850.
21. Biswas GD, Sparling PF Characterization of lbpA, the structural gene for a lactoferrin receptor in Neisseria gonorrhoeae. Infect Immun 1995, 63:2958-2967.
22. Chen CJ, Sparling PF, Lewis LA, et al. Identification and purification of a hemoglobin-binding outer membrane protein from Neisseria gonorrhoeae. Infect Immun 1996, 64:5008-5014.
23. Clark VL, Campbell LA, Palermo DA, et al. Induction and repression of outer membrane proteins by anaerobic growth of Neisseria gonorrhoeae. Infect Immun 1987, 55:1359-1364.
24. Barth KR, Isabella VM, Clark VL Biochemical and genomic analysis of the denitrification pathway within the genus Neisseria. Microbiology 2009, 155:4093-4103.
25. Elkins C, Carbonetti NH, Varela VA, et al. Antibodies to N-terminal peptides of gonococcal porin are bactericidal when gonococcal lipopolysaccharide is not sialylated. Mol Microbiol 1992, 6:2617-2628.
26. Garcia DL, Dillard JP Mutations in ampG or ampD affect peptidoglycan fragment release from Neisseria gonorrhoeae. J Bacteriol 2008, 190:3799-3807.
27. Fleming TJ, Wallsmith DE, Rosenthal RS Arthropathic properties of gonococcal peptidoglycan fragments: implications for the pathogenesis of disseminated gonococcal disease. Infect Immun 1986, 52:600-608.
28. Anderson B, Albritton WL, Biddle J, Johnson SR Common beta-lactamase-specifying plasmid in Haemophilus ducreyi and Neisseria gonorrhoeae. Antimicrob Agents Chemother 1984, 25:296-297.
29. Morse SA, Johnson SR, Biddle JW, Roberts MC High-level tetracycline resistance in Neisseria gonorrhoeae is result of acquisition of streptococcal tetM determinant. Antimicrob Agents Chemother 1986, 30:664-670.
30. Elkins C, Thomas CE, Seifert HS, Sparling PF Species-specific uptake of DNA by gonococci is mediated by a 10-base-pair sequence. J Bacteriol 1991, 173:3911-3913.
31. Shafer WM, Balthazar JT, Hagman KE, Morse SA Missense mutations that alter the DNA-binding domain of the MtrR protein occur frequently in rectal isolates of Neisseria gonorrhoeae that are resistant to faecal lipids. Microbiology 1995, 141(pt 4):907-911.
32. Spratt BG Hybrid penicillin-binding proteins in penicillin-resistant strains of Neisseria gonorrhoeae. Nature 1988, 332:173-176.
33. Centers for Disease Control and Prevention Sexually Transmitted Disease Surveillance, 2011 2012, U.S. Department of Health and Human Services, Atlanta.
34. Deguchi T, Yasuda M, Nakano M, et al. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob Agents Chemother 1996, 40:1020-1023.
35. Edwards JL, Apicella MA The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women. Clin Microbiol Rev 2004, 17:965-981.
36. Schneider H, Cross AS, Kuschner RA, et al. Experimental human gonococcal urethritis: 250 Neisseria gonorrhoeae MS11mkC are infective. J Infect Dis 1995, 172:180-185.
37. Harvey HA, Ketterer MR, Preston A, et al. Ultrastructural analysis of primary human urethral epithelial cell cultures infected with Neisseria gonorrhoeae. Infect Immun 1997, 65:2420-2427.
38. Ramsey KH, Schneider H, Cross AS, et al. Inflammatory cytokines produced in response to experimental human gonorrhea. J Infect Dis 1995, 172:186-191.
39. Harvey HA, Post DM, Apicella MA Immortalization of human urethral epithelial cells: a model for the study of the pathogenesis of and the inflammatory cytokine response to Neisseria gonorrhoeae infection. Infect Immun 2002, 70:5808-5815.
40. Apicella MA, Ketterer M, Lee FK, et al. The pathogenesis of gonococcal urethritis in men: confocal and immunoelectron microscopic analysis of urethral exudates from men infected with Neisseria gonorrhoeae. J Infect Dis 1996, 173:636-646.
41. Chen JC, Bavoil P, Clark VL Enhancement of the invasive ability of Neisseria gonorrhoeae by contact with HecIB, an adenocarcinoma endometrial cell line. Mol Microbiol 1991, 5:1531-1538.
42. Rudel T, Boxberger HJ, Meyer TF Pilus biogenesis and epithelial cell adherence of Neisseria gonorrhoeae pilC double knock-out mutants. Mol Microbiol 1995, 17:1057-1071.
43. 2- generation. J Biol Chem 1988, 263:945-951.
44. Mosleh IM, Huber LA, Steinlein P, et al. Neisseria gonorrhoeae porin modulates phagosome maturation. J Biol Chem 1998, 273:35332-35338.
45. Bjerknes R, Guttormsen HK, Solberg CO, Wetzler LM Neisserial porins inhibit human neutrophil actin polymerization, degranulation, opsonin receptor expression, and phagocytosis but prime the neutrophils to increase their oxidative burst. Infect Immun 1995, 63:160-167.
46. Farrell CF, Rest RF Up-regulation of human neutrophil receptors for Neisseria gonorrhoeae expressing PII outer membrane proteins. Infect Immun 1990, 58:2777-2784.
47. Harvey HA, Jennings MP, Campbell CA, et al. Receptor-mediated endocytosis of Neisseria gonorrhoeae into primary human urethral epithelial cells: the role of the asialoglycoprotein receptor. Mol Microbiol 2001, 42:659-672.
48. Giardina PC, Williams R, Lubaroff D, Apicella MA Neisseria gonorrhoeae induces focal polymerization of actin in primary human urethral epithelium. Infect Immun 1998, 66:3416-3419.
49. Zenni MK, Giardina PC, Harvey HA, et al. Macropinocytosis as a mechanism of entry into primary human urethral epithelial cells by Neisseria gonorrhoeae. Infect Immun 2000, 68:1696-1699.
50. Binnicker MJ, Williams RD, Apicella MA Gonococcal porin IB activates NF-kappaB in human urethral epithelium and increases the expression of host antiapoptotic factors. Infect Immun 2004, 72:6408-6417.
51. Binnicker MJ, Williams RD, Apicella MA Infection of human urethral epithelium with Neisseria gonorrhoeae elicits an upregulation of host anti-apoptotic factors and protects cells from staurosporine-induced apoptosis. Cell Microbiol 2003, 5:549-560.
52. John CM, Schneider H, Griffiss JM Neisseria gonorrhoeae that infect men have lipooligosaccharides with terminal N-acetyllactosamine repeats. J Biol Chem 1999, 274:1017-1025.
53. Campagnari AA, Spinola SM, Lesse AJ, et al. Lipooligosaccharide epitopes shared among gram-negative non-enteric mucosal pathogens. Microb Pathog 1990, 8:353-362.
54. Schneider H, Griffiss JM, Boslego JW, et al. Expression of paragloboside-like lipooligosaccharides may be a necessary component of gonococcal pathogenesis in men. J Exp Med 1991, 174:1601-1605.
55. Mandrell RE, Smith H, Jarvis GA, et al. Detection and some properties of the sialyltransferase implicated in the sialylation of lipopolysaccharide of Neisseria gonorrhoeae. Microb Pathog 1993, 14:307-313.
56. Mandrell RE, Griffiss JM, Macher BA Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes. J Exp Med 1988, 168:107-126.
57. Shell DM, Chiles L, Judd RC, et al. The Neisseria lipooligosaccharide-specific alpha-2,3-sialyltransferase is a surface-exposed outer membrane protein. Infect Immun 2002, 70:3744-3751.
58. McGee DJ, Rest RF Regulation of gonococcal sialyltransferase, lipooligosaccharide, and serum resistance by glucose, pyruvate, and lactate. Infect Immun 1996, 64:4630-4637.
59. McGee DJ, Chen GC, Rest RF Expression of sialyltransferase is not required for interaction of Neisseria gonorrhoeae with human epithelial cells and human neutrophils. Infect Immun 1996, 64:4129-4136.
60. Rest RF, Mandrell RE Neisseria sialytransferases and their role in pathogenesis. Microb Pathog 1995, 19:379-390.
61. Apicella MA, Mandrell RE, Shero M, et al. Modification by sialic acid of Neisseria gonorrhoeae lipooligosaccharide epitope expression in human urethral exudates: an immunoelectron microscopic analysis. J Infect Dis 1990, 162:506-512.
62. Parsons NJ, Patel PV, Tan EL, et al. Cytidine 5'-monophospho-N-acetyl neuraminic acid and a low molecular weight factor from human blood cells induce lipopolysaccharide alteration in gonococci when conferring resistance to killing by human serum. Microb Pathog 1988, 5:303-309.
63. Howe L, Wiggins R, Soothill PW, et al. Mucinase and sialidase activity of the vaginal microflora: implications for the pathogenesis of preterm labour. Int J STD AIDS 1999, 10:442-447.
64. Jakab L Sialidase activity in the cervical connective tissue. Orv Hetil 1994, 135:829.
65. Harvey HA, Porat N, Campbell CA, et al. Gonococcal lipooligosaccharide is a ligand for the asialoglycoprotein receptor on human sperm. Mol Microbiol 2000, 36:1059-1070.
66. Liu Y, Feinen B, Russell MW New concepts in immunity to Neisseria gonorrhoeae: innate responses and suppression of adaptive immunity favor the pathogen, not the host. Front Microbiol 2011, 2:52.
67. Edwards JL, Apicella MA The role of lipooligosaccharide in Neisseria gonorrhoeae pathogenesis of cervical epithelia: lipid A serves as a C3 acceptor molecule. Cell Microbiol 2002, 4:585-598.
68. Edwards JL, Brown EJ, Ault KA, Apicella MA The role of complement receptor 3 (CR3) in Neisseria gonorrhoeae infection of human cervical epithelia. Cell Microbiol 2001, 3:611-622.
69. Jarvis GA Analysis of C3 deposition and degradation on Neisseria meningitidis and Neisseria gonorrhoeae. Infect Immun 1994, 62:1755-1760.
70. McQuillen DP, Gulati S, Ram S, et al. Complement processing and immunoglobulin binding to Neisseria gonorrhoeae determined in vitro simulates in vivo effects. J Infect Dis 1999, 179:124-135.
71. Edwards JL, Shao JQ, Ault KA, Apicella MA Neisseria gonorrhoeae elicits membrane ruffling and cytoskeletal rearrangements upon infection of primary human endocervical and ectocervical cells. Infect Immun 2000, 68:5354-5363.
72. Edwards JL, Entz DD, Apicella MA Gonococcal phospholipase d modulates the expression and function of complement receptor 3 in primary cervical epithelial cells. Infect Immun 2003, 71:6381-6391.
73. Bolan GA, Ehrhardt A, Wasserheit JN Gender perspectives and STDs. Sexually Transmitted Diseases 1999, 117-127. McGraw-Hill, New York. 3rd ed. K.K. Holmes, P. Mardh, P.F. Sparling (Eds.).
74. Hasty LA, Lambris JD, Lessey BA, et al. Hormonal regulation of complement components and receptors throughout the menstrual cycle. Am J Obstet Gynecol 1994, 170:168-175.
75. Gorby GL, Clemens CM, Barley LR, McGee ZA Effect of human chorionic gonadotropin (hCG) on Neisseria gonorrhoeae invasion of and IgA secretion by human fallopian tube mucosa. Microb Pathog 1991, 10:373-384.
76. Spence JM, Tyler RE, Domaoal RA, Clark VL L12 enhances gonococcal transcytosis of polarized Hec1B cells via the lutropin receptor. Microb Pathog 2002, 32:117-125.
77. Reshef E, Lei ZM, Rao CV, et al. The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab 1990, 70:421-430.
78. Stephens DS, McGee ZA, Cooper MD Cytopathic effects of the pathogenic Neisseria: studies using human fallopian tube organ cultures and human nasopharyngeal organ cultures. Antonie van Leeuwenhoek 1987, 53:575-584.
79. Melly MA, McGee ZA, Rosenthal RS Ability of monomeric peptidoglycan fragments from Neisseria gonorrhoeae to damage human fallopian-tube mucosa. J Infect Dis 1984, 149:378-386.
80. Gregg CR, Melly MA, McGee ZA Gonococcal lipopolysaccharide: a toxin for human fallopian tube mucosa. Am J Obstet Gynecol 1980, 138:981-984.
81. Gregg CR, Johnson AP, Taylor-Robinson D, et al. Host species-specific damage to oviduct mucosa by Neisseria gonorrhoeae lipopolysaccharide. Infect Immun 1981, 34:1056-1058.
82. McGee ZA, Clemens CM, Jensen RL, et al. Local induction of tumor necrosis factor as a molecular mechanism of mucosal damage by gonococci. Microb Pathog 1992, 12:333-341.
83. Weinstock H, Berman S, Cates W Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004, 36:6-10.
84. Glasier A, Gulmezoglu AM, Schmid GP, et al. Sexual and reproductive health: a matter of life and death. Lancet 2006, 368:1595-1607.
85. Paz-Bailey G, Rahman M, Chen C, et al. Changes in the etiology of sexually transmitted diseases in Botswana between 1993 and 2002: implications for the clinical management of genital ulcer disease. Clin Infect Dis 2005, 41:1304-1312.
86. Gorgos L, Newman L, Satterwhite C, et al. Gonorrhoea positivity among women aged 15-24 years in the USA, 2005-2007. Sex Transm Infect 2011, 87:202-204.
87. Torrone EA, Johnson RE, Tian LH, et al. Prevalence of Neisseria gonorrhoeae among persons 14 to 39 years of age, United States, 1999 to 2008. Sex Transm Dis 2013, 40:202-205.
88. Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004, 291:2229-2236.
89. Newman LM, Dowell D, Bernstein K, et al. A tale of two gonorrhea epidemics: results from the STD surveillance network. Public Health Rep 2012, 127:282-292.
90. Kerani RP, Handcock MS, Handsfield HH, Holmes KK Comparative geographic concentrations of 4 sexually transmitted infections. Am J Public Health 2005, 95:324-330.
91. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005, 41:67-74.
92. Marcus JL, Bernstein KT, Kohn RP, et al. Infections missed by urethral-only screening for chlamydia or gonorrhea detection among men who have sex with men. Sex Transm Dis 2011, 38:922-924.
93. Dicker LW, Mosure DJ, Berman SM, Levine WC Gonorrhea prevalence and coinfection with chlamydia in women in the United States, 2000. Sex Transm Dis 2003, 30:472-476.
94. Barry PM, Kent CK, Klausner JD Risk factors for gonorrhea among heterosexuals-San Francisco, 2006. Sex Transm Dis 2009, 36(2 suppl):S62-S66.
95. Hooper RR, Reynolds GH, Jones OG, et al. Cohort study of venereal disease, I: The risk of gonorrhea transmission from infected women to men. Am J Epidemiol 1978, 108:136-144.
96. Lin JS, Donegan SP, Heeren TC, et al. Transmission of Chlamydia trachomatis and Neisseria gonorrhoeae among men with urethritis and their female sex partners. J Infect Dis 1998, 178:1707-1712.
97. Mohllajee AP, Curtis KM, Martins SL, Peterson HB Hormonal contraceptive use and risk of sexually transmitted infections: a systematic review. Contraception 2006, 73:154-165.
98. Jennings JM, Curriero FC, Celentano D, Ellen JM Geographic identification of high gonorrhea transmission areas in Baltimore, Maryland. Am J Epidemiol 2005, 161:73-80.
99. Ellen JM, Brown BA, Chung SE, et al. Impact of sexual networks on risk for gonorrhea and chlamydia among low-income urban African American adolescents. J Pediatr 2005, 146:518-522.
100. Fichtenberg CM, Muth SQ, Brown B, et al. Sexual network structure among a household sample of urban African American adolescents in an endemic sexually transmitted infection setting. Sex Transm Dis 2009, 36:41-48.
101. Handsfield HH, Lipman TO, Harnisch JP, et al. Asymptomatic gonorrhea in men: diagnosis, natural course, prevalence and significance. N Engl J Med 1974, 290:117-123.
102. Dillon JA, Yeung KH Beta-lactamase plasmids and chromosomally mediated antibiotic resistance in pathogenic Neisseria species. Clin Microbiol Rev 1989, 2(suppl):S125-S133.
103. Morse SA, Lysko PG, McFarland L, et al. Gonococcal strains from homosexual men have outer membranes with reduced permeability to hydrophobic molecules. Infect Immun 1982, 37:432-438.
104. Wang SA, Harvey AB, Conner SM, et al. Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance. Ann Intern Med 2007, 147:81-88.
105. Aplasca D, Pato-Mesola V, Klausner JD, et al. A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines. Clin Infect Dis 2001, 32:1313-1318.
106. Centers for Disease Control and Prevention Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012, 61:590-594.
107. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013, 309:163-170.
108. Carnicer-Pont D, Smithson A, Fina-Homar E, Bastida MT First cases of Neisseria gonorrhoeae resistant to ceftriaxone in Catalonia, Spain, May 2011. Enferm Infecc Microb Clin 2012, 30:218-219. Gonococcus Antimicrobial Resistance Surveillance Working Group.
109. Unemo M, Golparian D, Stary A, Eigentler A First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill 2011, 16:19998.
110. Lewis DA, Sriruttan C, Muller EE, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013, 68:1267-1270.
111. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012, 56:1273-1280.
112. Kirkcaldy RD, Zaidi A, Hook EW, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005-2010. Ann Intern Med 2013, 158:321-328.
113. Kirkcaldy RD, Ballard RC, Dowell D Gonococcal resistance: are cephalosporins next?. Curr Infect Dis Rep 2011, 13:196-204.
114. Soge OO, Harger D, Schafer S, et al. Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). Sex Transm Dis 2012, 39:877-879.
115. Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis 2012, 54:841-843.
116. Cohen MS, Cannon JG Human experimentation with Neisseria gonorrhoeae: progress and goals. J Infect Dis 1999, 179(suppl 2):S375-S379.
117. Brunham RC, Plummer F, Slaney L, et al. Correlation of auxotype and protein I type with expression of disease due to Neisseria gonorrhoeae. J Infect Dis 1985, 152:339-343.
118. Berger RE, Alexander ER, Harnisch JP, et al. Etiology, manifestations and therapy of acute epididymitis: prospective study of 50 cases. J Urol 1979, 121:750-754.
119. Platt R, Rice PA, McCormack WM Risk of acquiring gonorrhea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhea. JAMA 1983, 250:3205-3209.
120. McCormack WM, Stumacher RJ, Johnson K, Donner A Clinical spectrum of gonococcal infection in women. Lancet 1977, 1:1182-1185.
121. Brunham RC, Paavonen J, Stevens CE, et al. Mucopurulent cervicitis-the ignored counterpart in women of urethritis in men. N Engl J Med 1984, 311:1-6.
122. Barry PM, Kent CK, Philip SS, Klausner JD Results of a program to test women for rectal chlamydia and gonorrhea. Obstet Gynecol 2010, 115:753-759.
123. Klausner JD, Kohn R, Kent C Etiology of clinical proctitis among men who have sex with men. Clin Infect Dis 2004, 38:300-302.
124. Park J, Marcus JL, Pandori M, et al. Sentinel surveillance for pharyngeal chlamydia and gonorrhea among men who have sex with men-San Francisco, 2010. Sex Transm Dis 2012, 39:482-484.
125. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:651-681.
126. Walker CK, Wiesenfeld HC Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2007, 44(suppl 3):S111-S122.
127. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001, 185:380-385.
128. Ness RB, Soper DE, Holley RL, et al. Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study. Am J Obstet Gynecol 2001, 185:121-127.
129. Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002, 100:456-463.
130. Ness RB, Kip KE, Hillier SL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol 2005, 162:585-590.
131. Westrom L, Joesoef R, Reynolds G, et al. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992, 19:185-192.
132. Ness RB, Soper DE, Peipert J, et al. Design of the PID Evaluation and Clinical Health (PEACH) Study. Control Clin Trials 1998, 19:499-514.
133. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002, 186:929-937.
134. Haggerty CL, Schulz R, Ness RB Lower quality of life among women with chronic pelvic pain after pelvic inflammatory disease. Obstet Gynecol 2003, 102:934-939.
135. Burgis JT, Nawaz H Disseminated gonococcal infection in pregnancy presenting as meningitis and dermatitis. Obstet Gynecol 2006, 108:798-801.
136. Bleich AT, Sheffield JS, Wendel GD, et al. Disseminated gonococcal infection in women. Obstet Gynecol 2012, 119:597-602.
137. Golden MR. Personal communication: 2008.
138. Ellison RT, Curd JG, Kohler PF, et al. Underlying complement deficiency in patients with disseminated gonococcal infection. Sex Transm Dis 1987, 14:201-204.
139. Rice P, Handsfield HH Arthritis associated with sexually transmitted diseases. Sexually Transmitted Diseases 2008, McGraw-Hill, New York. 4th ed. K.K. Holmes, P.F. Sparling, P. Mardh (Eds.).
140. Read P, Abbott R, Pantelidis P, et al. Disseminated gonococcal infection in a homosexual man diagnosed by nucleic acid amplification testing from a skin lesion swab. Sex Transm Infect 2008, 84:348-349.
141. Jackman JD, Glamann DB Gonococcal endocarditis: twenty-five year experience. Am J Med Sci 1991, 301:221-230.
142. Woods CR Gonococcal infections in neonates and young children. Semin Pediatr Infect Dis 2005, 16:258-270.
143. Janda WM, Bohnoff M, Morello JA, Lerner SA Prevalence and site-pathogen studies of Neisseria meningitidis and N gonorrhoeae in homosexual men. JAMA 1980, 244:2060-2064.
144. Maini M, French P, Prince M, Bingham JS Urethritis due to Neisseria meningitidis in a London genitourinary medicine clinic population. Int J STD AIDS 1992, 3:423-425.
145. Golden MR, Hughes JP, Cles LE, et al. Positive predictive value of Gen-Probe APTIMA Combo 2 testing for Neisseria gonorrhoeae in a population of women with low prevalence of N. gonorrhoeae infection. Clin Infect Dis 2004, 39:1387-1390.
146. Bachmann LH, Desmond RA, Stephens J, et al. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea. J Clin Microbiol 2002, 40:3596-3601.
147. Schachter J, Moncada J, Liska S, et al. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008, 35:637-642.
148. Goldenberg SD, Finn J, Sedudzi E, et al. Performance of the GeneXpert CT/NG assay compared to that of the Aptima AC2 assay for detection of rectal Chlamydia trachomatis and Neisseria gonorrhoeae by use of residual Aptima Samples. J Clin Microbiol 2012, 50:3867-3869.
149. McNally LP, Templeton DJ, Jin F, et al. Low positive predictive value of a nucleic acid amplification test for nongenital Neisseria gonorrhoeae infection in homosexual men. Clin Infect Dis 2008, 47:e25-e27.
150. Ison CA Laboratory methods in genitourinary medicine: methods of diagnosing gonorrhoea. Genitourin Med 1990, 66:453-459.
151. Newman LM, Moran JS, Workowski KA Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007, 44(suppl 3):S84-S101.
152. Datta SD, Sternberg M, Johnson RE, et al. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. Ann Intern Med 2007, 147:89-96.
153. DePestel DD, Benninger MS, Danziger L, et al. Cephalosporin use in treatment of patients with penicillin allergies. J Am Pharm Assoc (2003) 2008, 48:530-540.
154. Bernstein KT, Zenilman J, Olthoff G, et al. Gonorrhea reinfection among sexually transmitted disease clinic attendees in Baltimore, Maryland. Sex Transm Dis 2006, 33:80-86.
155. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005, 352:676-685.
156. Peterman TA, Tian LH, Metcalf CA, et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med 2006, 145:564-572.
157. Workowski KA, Berman S Sexually transmitted disease treatment guidelines. MMWR Recomm Rep 2010, 59(RR-12):1-110. Centers for Disease Control and Prevention.
158. Hogben M Partner notification for sexually transmitted diseases. Clin Infect Dis 2007, 44(suppl 3):S160-S174.
159. Golden MR, Hogben M, Handsfield HH, et al. Partner notification for HIV and STD in the United States: low coverage for gonorrhea, chlamydial infection, and HIV. Sex Transm Dis 2003, 30:490-496.
160. Meyers D, Wolff T, Gregory K, et al. USPSTF recommendations for STI screening. Am Fam Physician 2008, 77:819-824.
161. Manhart LE, Marrazzo JM, Fine DN, et al. Selective testing criteria for gonorrhea among young women screened for chlamydial infection: contribution of race and geographic prevalence. J Infect Dis 2007, 196:731-737.
162. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997, 349:1868-1873.
163. Marrazzo JM, Cates W Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis 2011, 53(suppl 3):S64-S78.
164. Warner L, Stone KM, Macaluso M, et al. Condom use and risk of gonorrhea and chlamydia: a systematic review of design and measurement factors assessed in epidemiologic studies. Sex Transm Dis 2006, 33:36-51.
165. French PP, Latka M, Gollub EL, et al. Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. Sex Transm Dis 2003, 30:433-439.
166. Ramjee G, van der Straten A, Chipato T, et al. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One 2008, 3:e3488.
167. Richardson BA Nonoxynol-9 as a vaginal microbicide for prevention of sexually transmitted infections: it's time to move on. JAMA 2002, 287:1171-1172.
168. Harrison WO, Hooper RR, Wiesner PJ, et al. A trial of minocycline given after exposure to prevent gonorrhea. N Engl J Med 1979, 300:1074-1078.
169. Boslego JW, Tramont EC, Chung RC, et al. Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine 1991, 9:154-162.
170. Bolan GA, Sparling PF, Wasserheit JN The emerging threat of untreatable gonococcal infection. N Engl J Med 2012, 366:485-487.
171. Kurre R, Hone A, Clausen M, et al. PilT2 enhances the speed of gonococcal type IV pilus retraction and of twitching motility. Mol Microbiol 2012, 86:857-865.
172. Janda W, Gaydos C Neisseria. Manual of Clinical Microbiology 2007, American Society of Microbiology, Washington, DC. 9th ed. P.R. Murray, E.J. Baron, J.H. Jorgensen (Eds.).
173. Chen CJ, Tobiason DM, Thomas CE, et al. A mutant form of the Neisseria gonorrhoeae pilus secretin protein PilQ allows increased entry of heme and antimicrobial compounds. J Bacteriol 2004, 186:730-739.
174. Schoolnik GK, Fernandez R, Tai JY, et al. Gonococcal pili: primary structure and receptor binding domain. J Exp Med 1984, 159:1351-1370.
175. Forest KT, Bernstein SL, Getzoff ED, et al. Assembly and antigenicity of the Neisseria gonorrhoeae pilus mapped with antibodies. Infect Immun 1996, 64:644-652.
176. Kellogg DS, Peacock WL, Deacon WE, et al. Neisseria gonorrhoeae, I. Virulence genetically linked to clonal variation. J Bacteriol 1963, 85:1274-1279.
177. McGee ZA, Johnson AP, Taylor-Robinson D Pathogenic mechanisms of Neisseria gonorrhoeae: observations on damage to human fallopian tubes in organ culture by gonococci of colony type 1 or type 4. J Infect Dis 1981, 143:413-422.
178. Kirchner M, Heuer D, Meyer TF CD46-independent binding of neisserial type IV pili and the major pilus adhesin, PilC, to human epithelial cells. Infect Immun 2005, 73:3072-3082.
179. Barth KR, Isabella VM, Clark VL Biochemical and genomic analysis of the denitrification pathway within the genus Neisseria. Microbiology 2009, 155:4093-4103.
180. Elkins C, Carbonetti NH, Varela VA, et al. Antibodies to N-terminal peptides of gonococcal porin are bactericidal when gonococcal lipopolysaccharide is not sialylated. Mol Microbiol 1992, 6:2617-2628.
181. Garcia DL, Dillard JP Mutations in ampG or ampD affect peptidoglycan fragment release from Neisseria gonorrhoeae. J Bacteriol 2008, 190:3799-3807.
182. Fleming TJ, Wallsmith DE, Rosenthal RS Arthropathic properties of gonococcal peptidoglycan fragments: implications for the pathogenesis of disseminated gonococcal disease. Infect Immun 1986, 52:600-608.
183. Anderson B, Albritton WL, Biddle J, Johnson SR Common beta-lactamase-specifying plasmid in Haemophilus ducreyi and Neisseria gonorrhoeae. Antimicrob Agents Chemother 1984, 25:296-297.
184. Morse SA, Johnson SR, Biddle JW, Roberts MC High-level tetracycline resistance in Neisseria gonorrhoeae is result of acquisition of streptococcal tetM determinant. Antimicrob Agents Chemother 1986, 30:664-670.
185. Elkins C, Thomas CE, Seifert HS, Sparling PF Species-specific uptake of DNA by gonococci is mediated by a 10-base-pair sequence. J Bacteriol 1991, 173:3911-3913.
186. Shafer WM, Balthazar JT, Hagman KE, Morse SA Missense mutations that alter the DNA-binding domain of the MtrR protein occur frequently in rectal isolates of Neisseria gonorrhoeae that are resistant to faecal lipids. Microbiology 1995, 141(pt 4):907-911.
187. Spratt BG Hybrid penicillin-binding proteins in penicillin-resistant strains of Neisseria gonorrhoeae. Nature 1988, 332:173-176.
188. Centers for Disease Control and Prevention Sexually Transmitted Disease Surveillance, 2011 2012, U.S. Department of Health and Human Services, Atlanta.
189. Deguchi T, Yasuda M, Nakano M, et al. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob Agents Chemother 1996, 40:1020-1023.
190. Edwards JL, Apicella MA The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women. Clin Microbiol Rev 2004, 17:965-981.
191. Bjerknes R, Guttormsen HK, Solberg CO, Wetzler LM Neisserial porins inhibit human neutrophil actin polymerization, degranulation, opsonin receptor expression, and phagocytosis but prime the neutrophils to increase their oxidative burst. Infect Immun 1995, 63:160-167.
192. Binnicker MJ, Williams RD, Apicella MA Gonococcal porin IB activates NF-kappaB in human urethral epithelium and increases the expression of host antiapoptotic factors. Infect Immun 2004, 72:6408-6417.
193. Gorgos L, Newman L, Satterwhite C, et al. Gonorrhoea positivity among women aged 15-24 years in the USA, 2005-2007. Sex Transm Infect 2011, 87:202-204.
194. Torrone EA, Johnson RE, Tian LH, et al. Prevalence of Neisseria gonorrhoeae among persons 14 to 39 years of age, United States, 1999 to 2008. Sex Transm Dis 2013, 40:202-205.
195. Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004, 291:2229-2236.
196. Newman LM, Dowell D, Bernstein K, et al. A tale of two gonorrhea epidemics: results from the STD surveillance network. Public Health Rep 2012, 127:282-292.
197. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005, 41:67-74.
198. Marcus JL, Bernstein KT, Kohn RP, et al. Infections missed by urethral-only screening for chlamydia or gonorrhea detection among men who have sex with men. Sex Transm Dis 2011, 38:922-924.
199. Centers for Disease Control and Prevention Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012, 61:590-594.
200. Unemo M, Golparian D, Stary A, Eigentler A First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill 2011, 16:19998.
201. Lewis DA, Sriruttan C, Muller EE, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013, 68:1267-1270.
202. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012, 56:1273-1280.
203. Kirkcaldy RD, Zaidi A, Hook EW, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005-2010. Ann Intern Med 2013, 158:321-328.
204. Kirkcaldy RD, Ballard RC, Dowell D Gonococcal resistance: are cephalosporins next?. Curr Infect Dis Rep 2011, 13:196-204.
205. Soge OO, Harger D, Schafer S, et al. Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). Sex Transm Dis 2012, 39:877-879.
206. Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis 2012, 54:841-843.
207. Cohen MS, Cannon JG Human experimentation with Neisseria gonorrhoeae: progress and goals. J Infect Dis 1999, 179(suppl 2):S375-S379.
208. Brunham RC, Plummer F, Slaney L, et al. Correlation of auxotype and protein I type with expression of disease due to Neisseria gonorrhoeae. J Infect Dis 1985, 152:339-343.
209. Klausner JD, Kohn R, Kent C Etiology of clinical proctitis among men who have sex with men. Clin Infect Dis 2004, 38:300-302.
210. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001, 185:380-385.
211. Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002, 100:456-463.
212. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002, 186:929-937.
213. Rice P, Handsfield HH Arthritis associated with sexually transmitted diseases. Sexually Transmitted Diseases 2008, McGraw-Hill, New York. 4th ed. K.K. Holmes, P.F. Sparling, P. Mardh (Eds.).
214. Golden MR, Hughes JP, Cles LE, et al. Positive predictive value of Gen-Probe APTIMA Combo 2 testing for Neisseria gonorrhoeae in a population of women with low prevalence of N. gonorrhoeae infection. Clin Infect Dis 2004, 39:1387-1390.
215. Bachmann LH, Desmond RA, Stephens J, et al. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea. J Clin Microbiol 2002, 40:3596-3601.
216. Schachter J, Moncada J, Liska S, et al. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008, 35:637-642.
217. Newman LM, Moran JS, Workowski KA Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007, 44(suppl 3):S84-S101.
218. Datta SD, Sternberg M, Johnson RE, et al. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. Ann Intern Med 2007, 147:89-96.
219. Bernstein KT, Zenilman J, Olthoff G, et al. Gonorrhea reinfection among sexually transmitted disease clinic attendees in Baltimore, Maryland. Sex Transm Dis 2006, 33:80-86.
220. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005, 352:676-685.
221. Golden MR, Hogben M, Handsfield HH, et al. Partner notification for HIV and STD in the United States: low coverage for gonorrhea, chlamydial infection, and HIV. Sex Transm Dis 2003, 30:490-496.
222. Manhart LE, Marrazzo JM, Fine DN, et al. Selective testing criteria for gonorrhea among young women screened for chlamydial infection: contribution of race and geographic prevalence. J Infect Dis 2007, 196:731-737.
223. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997, 349:1868-1873.
224. Marrazzo JM, Cates W Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis 2011, 53(suppl 3):S64-S78.
225. Warner L, Stone KM, Macaluso M, et al. Condom use and risk of gonorrhea and chlamydia: a systematic review of design and measurement factors assessed in epidemiologic studies. Sex Transm Dis 2006, 33:36-51.